Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is CCAJ still acquiring Advanced Warning Systems (AWS)...I just looked at the website (link below) today for the first time and looks like a promising acquisition.
AWS is still listed on the CCAJ website as an acquisition target.
https://www.aws-scan.com/
At least $.05 would be nice to see again!
This is what we are waiting for from SBFM: "Adva-27a is expected to enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast cancer following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection."
I would think an update on this is forthcoming within the next 4 months. By then we should also have an indication of the status of the NAS listing. If both are positive then good for those who have bought and held. If not, then all bets are off.
That would be the bad news. The good news would be SBFM is ready to start clinical trials (of cancer treatment) in early 2023 leading to FDA compassionate use authorization in late 2023! Just sayin' it can go either way or somewhere in between. 4-7 months of patience to find out whether they stay listed on the NAS and if they do have a cancer drug ready for human clinical trials in 2023.
Was SBFM on the NAS back then or is this the new part this time around?
Great, that gives SBFM 7 months to show the goods! That would be April 2023. I think we'll get a significant update (good or bad) by January 2023. We'll also know if the stock price is going back up by then!
4-7 months until we know if SBFM is a make the bank or break the bank stock.
OTC Markets CCAJ status change coming soon.....
From CCAJ website FAQs: "We are targeting End of the 4th Quarter of 2022 to become fully reporting, but will put the status at Pink Current by the end of the 3rd Quarter."
SBFM "estimates that it will take approximately 18 to 24 months from start to finish. Following successful completion of Phase I clinical trials, it is likely that we will be required to make Adva-27a available to patients under the “compassionate-use” guidelines."
SBFM said this about 7 months ago so they are down to 11-17 months which is why we should get a substantial update by early 2023 which takes off another 4-5 months of this timeline making it 6-12 months.
I'm holding and accumulating a bit more to see where this goes in 2023. And this is just based on the Cancer treatment becoming available to patients in late 2023.
The timeframe for progress also comes from the SBFM website:
Adva-27a Clinical Trials Plans
Adva-27a’s initial indication for Phase I clinical trials will be pancreatic cancer. We are planning to conduct our clinical trials at McGill University’s Jewish General Hospital in Montreal, Canada. All aspects of the planned clinical trials in Canada will employ FDA standards at all levels. We estimate that it will take approximately 18 to 24 months from start to finish. Following successful completion of Phase I clinical trials, it is likely that we will be required to make Adva-27a available to patients under the “compassionate-use” guidelines.
Excellent! We will finally know what is going on and maybe before 2023 when I suspect we will find out something even if not through your complaints. In their last few reports they have said it will take many more months to make progress so that is why I keep saying 2023 is the year for finding out what they are up to. If your complaints lead to earlier knowledge by forcing their hand, I'm all for it.
Surfer, since you almost bought this shell a few years ago, what do you see in the New Management, New AS and the New Focus on Luxury Home Development?
I've got some extra cash so planning to buy anywhere between $.003-.004 if it continues to uptrend next week and beyond.
Why?
This 2-bit vitamin reseller may become a 4-bit vitamin reseller after their large-scale international marketing campaign. Perhaps they will sell millions of bottles!
You never know what will happen in 2023. Perhaps that is also the year (finally) for FDA IND approval.
Hit $.003 today. Does that mean we are all buying at $.003+ next week?
Maybe in 2023 somewhere between $30-100
Great news. Maybe SBFM will get 1/152 of the Market or $1B in the next 5 years. If I'm doing my math right they just need to sell 50,000,000 bottles at $20/bottle. That is only 10 bottles bought by 5,000,000 people. There are 350,000,000+ people in the US and billions more across the planet. Seems doable with an excellent international marketing team and large-scale marketing campaign! I will buy 10 bottles over the next 1-2 years to help the cause.
Yes, probably a quiet period until 2023. We'll see who can make it that long. As of now, I plan to see this through another 6-12 months.
I was looking for a few more in the low $.002s this week ...but now looks like the high $.002s!
Not entirely, but more on the fact they have stated some of the development of their drugs will take that long to get to clinical trials. I think that we are in a relative quiet period, but will hear much more in 2023 regarding development of drugs. Patience over the next 6-9 months is required and some on this board have lost their patience which is understandable.
Or they strike oil and gold in 2023!
Looking for another push to $.02 this week. I'm buying more up to $.02.
For me, the dream has just been delayed. I'm looking for much more progress on the SBFM dream over the next 9 months. Approximately 12 months after the NAS uplist we should have a much clearer picture. Whether to buy, sell or hold is up to each of us. I just happen to be buying and holding for another 9 months or so.
Perhaps $0.015 is the launchpad to $0.15 within days or weeks!
Yes, they are real. I bought 3 times from Amazon and feel better when taking them.
Will AXXA go over $.02 again on Friday?
Okay, let's talk again in 2023 when this is either in the ground or on the moon!
Be nice to the Dr. who can shock the world!
This is and will be a long shot, but check back in 2023 if you don't like it now.
NOLF says anticipated filing date is August 18th so looks like they want it out before the weekend.
Give me $20 and I'll be living the dream! Give me $100 and I'll be living the dream and more!
How does SBFM go from $1.20/share to $250 in 2023? I'm still optimistic about $20-40 by 2023, but can't see or smell $250. What is your basis for that prediction?
I believe! At least for 9-12 more months. Maybe SBFM won't cure cancer, but they found some mRNA molecules that destroy cancer cells (see below). I'll wait for more about this before deciding whether to continue holding or selling.
K1.1 Anti-cancer mRNA: In June 2021, we initiated a new research project in which we set out to determine if certain mRNA molecules can be used as anti-cancer agents. The data collected to date have shown that a selected group of mRNA molecules are capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Other studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little cytotoxic effects. These new mRNA molecules, bearing the laboratory name K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology. In April 2022, we filed a provisional patent application in the United States covering the subject mRNA molecules. We plan to commence mice xenograft studies within approximately the next twelve months.
Looks like anything under $.02 is a good price going forward. I'll be adding a few more in that range early this week.
All of that post was related to SEC communication, not FDA. The post is no longer there.
A positive IND Study/FDA update is what we need for the cancer drug SBFM is working on.
Proper News would be that SBFM has received approval from the FDA for an IND study (see requirements below) and has a start date for the study. This would be an excellent update to what was reported on May 26: "SBFM is reporting steps to begin an investigational new drug (IND) study of an anticancer drug the oncology-focused biopharmaceutical company is developing — and recently announced that two of its newly designed mRNA molecules are effective at destroying cancer cells grown in culture. The use of mRNA could prove a powerful ally in the fight against cancer."
IND Application Requirements: The IND application must contain information in three broad areas:
Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
Manufacturing Information - Information pertaining to the composition, manufacturer, stability, and controls used for manufacturing the drug substance and the drug product. This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug.
Clinical Protocols and Investigator Information - Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks. Also, information on the qualifications of clinical investigators--professionals (generally physicians) who oversee the administration of the experimental compound--to assess whether they are qualified to fulfill their clinical trial duties. Finally, commitments to obtain informed consent from the research subjects, to obtain review of the study by an institutional review board (IRB), and to adhere to the investigational new drug regulations.
Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.
I think SBFM will get back to $4+ within next 3-6 months. After that moves on to $8-10+ when they give an update related to FDA fast track for the cancer drug.
Looking forward to an AXXA price range between $.20-.50 sometime in 2022 and beyond that in 2023. Do you agree?
Not sure about $2, but maybe $.50 especially if they do a buyback to reduce OS.
Starting what?